May 2026
1. ACUNA M, Martin-Munoz JC, Munoz MJ, Casado FD, et al
   A Naturalistic Study on the Cost Reduction and Efficacy of Long-acting Antipsychotics in an Early Intervention Programme for Patients with Recent-onset Psychosis.
   Pharmacopsychiatry. 2026 May 29. doi: 10.1055/a-2865-3839.
   

   >> Share

   
   
2. HART XM, Hirjak D, Eap CB, Eichentopf L, et al
   High Clozapine Serum Levels Do Not Improve Response: An Observational Study in Patients with Schizophrenia Treated with Clozapine in a Naturalistic Setting.
   Pharmacopsychiatry. 2026 May 20. doi: 10.1055/a-2868-3000.
   

   >> Share

   
   November 2025
3. NADER G, Yung A, Liang Y, Ducharme M, et al
   Antipsychotic Polypharmacy and Epigenetic Age Acceleration in Schizophrenia.
   Pharmacopsychiatry. 2025 Nov 3. doi: 10.1055/a-2668-0722.
   

   >> Share

   
   September 2025
4. CENDROS M, Catalan R, Torra M, Penades R, et al
   Influence of Glutamate Neurotransmission Genes on the Outcomes of Antipsychotic Treatments.
   Pharmacopsychiatry. 2025;58:205-215.
   

   >> Share

   
   January 2025
5. KISHI T, Citrome L, Sakuma K, Hamanaka S, et al
   Xanomeline-Trospium for Adults with Schizophrenia Experiencing Acute Psychosis: A Systematic Review and Meta-analysis of Safety and Tolerability Outcomes.
   Pharmacopsychiatry. 2025 Jan 29. doi: 10.1055/a-2506-7022.
   

   >> Share

   
   November 2024
6. FERNANDO P, Strauss J, Wagner E, Lohrs L, et al
   Early Treatment-Resistance in First Episode Psychosis.
   Pharmacopsychiatry. 2024 Nov 15. doi: 10.1055/a-2421-2411.
   

   >> Share

   
   
7. QU K, He Y, Zhang Z, Cao Y, et al
   Association Study Between DRD2, DRD3 Genetic Polymorphisms and Adverse Reactions in Chinese Patients on Amisulpride Treatment.
   Pharmacopsychiatry. 2024;57:283-289.
   

   >> Share

   
   
8. DEN TOOM M, Blanken L, Horn I, Veerman S, et al
   Electroconvulsive Therapy Versus Aripiprazole Addition to Clozapine in Patients with Clozapine-Resistant Symptoms (EMECLO): A Protocol of a Single-Blind, Multicenter, Randomized-Controlled Feasibility Trial.
   Pharmacopsychiatry. 2024;57:290-295.
   

   >> Share

   
   May 2024
9. KOMATSU Y, Takehara M, Hart X, Takahashi Y, et al
   Advancements in Non-Dopaminergic Treatments for Schizophrenia: A Systematic Review of Pipeline Developments.
   Pharmacopsychiatry. 2024 May 6. doi: 10.1055/a-2307-6484.
   

   >> Share

   
   April 2024
10. LLORCA-BOFI V, Bioque M, Madero S, Mallorqui A, et al
    Blood Cell Count Ratios at Baseline are Associated with Initial Clinical Response to Clozapine in Treatment-Resistant, Clozapine-Naive, Schizophrenia-Spectrum Disorder.
    Pharmacopsychiatry. 2024 Apr 15. doi: 10.1055/a-2290-6386.
    

    >> Share

    
    February 2024
11. HART XM, Mitsukura Y, Bies RR, Uchida H, et al
    Unraveling the Influence of Age, IQ, Education, and Negative Symptoms on Neurocognitive Performance in Schizophrenia: A Conditional Inference Tree Analysis.
    Pharmacopsychiatry. 2024 Feb 22. doi: 10.1055/a-2258-0379.
    

    >> Share

    
    January 2024
12. BREIT S, Meyer A, Schmitt W, Bracht T, et al
    The Effect of Electroconvulsive Therapy on Specific Catatonia Symptoms and Predictors of Late Response.
    Pharmacopsychiatry. 2024;57:13-20.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share